NCT04479514 is a Phase 2 clinical trial of Warm Baths or Showers in Pediatric Cancer, sponsored by Dana-Farber Cancer Institute.

Who is sponsoring NCT04479514?

NCT04479514 is sponsored by Dana-Farber Cancer Institute.

What drugs are being tested in NCT04479514?

Interventions in NCT04479514: Warm Baths or Showers, Moisturizer, SPF 30 or Higher Suncreen, Sun Protective Clothing, Limited Sun Exposure, Dilute bleach baths.

What condition does NCT04479514 study?

NCT04479514 studies Pediatric Cancer, CNS Tumor, Childhood, Skin Inflammation.

Is NCT04479514 still recruiting?

NCT04479514 is currently completed. Last updated 1 May 2025.

Are results published for NCT04479514?

Yes — primary outcome results have been posted to ClinicalTrials.gov. See the outcomes section above for details.

Last reviewed 2025-05-01 · How we verify

NCT04479514

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Preventative Skin Care for Children Undergoing Targeted CNS Tumor Therapy

Completed Phase 2 Results posted Last updated 1 May 2025

What this trial tests

Phase 2 trial testing Warm Baths or Showers in Pediatric Cancer in 14 participants. Completed in 15 February 2025.

Timeline

1 October 2020

Primary endpoint
1 January 2024

15 February 2025

Quick facts

Lead sponsor	Dana-Farber Cancer Institute
Phase	Phase 2
Status	Completed
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	supportive care
Enrollment	14
Start date	1 October 2020
Primary completion	1 January 2024
Estimated completion	15 February 2025
Sites	2 locations across United States

Drugs / interventions tested

Warm Baths or Showers
Moisturizer — full drug profile →
SPF 30 or Higher Suncreen — full drug profile →
Sun Protective Clothing
Limited Sun Exposure
Dilute bleach baths

Conditions studied

Pediatric Cancer — all drugs for Pediatric Cancer →
CNS Tumor, Childhood — all drugs for CNS Tumor, Childhood →
Skin Inflammation — all drugs for Skin Inflammation →

Sponsor

Dana-Farber Cancer Institute

Who can join

Adults 6 Months to 18, any sex, with Pediatric Cancer or CNS Tumor, Childhood. Patients with the condition only — healthy volunteers not accepted.

Results — posted to ClinicalTrials.gov

Per-arm endpoint measurements with 95% confidence intervals where reported. Source: trial results section.

Rate of Cutaneous Reaction Primary · 12 weeks

Proportion (percentage) of patients with one or more cutaneous reaction to targeted BRAF, MEK, or Pan-RAF inhibitor therapy

Group	Value	95% CI
Preventative Skin Care Routine	7

Sponsor's own description

This research study is examining a preventive skin care regimen for children diagnosed with a brain tumor and receiving anti-cancer therapy with a MEK, Pan-RAF, or BRAF inhibitor.

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other recruiting trials for Pediatric Cancer

Currently open trials in the same condition.

NCT07506239 — Efficacy of Laser Interstitial Thermal Therapy in Young Persons With Low-grade Glioma · NA · recruiting
NCT07278778 — Cancer Care Companion · NA · recruiting
NCT07473518 — Thyroid Carcinoma in Cancer Patients Undergoing Radiotherapy · recruiting
NCT06939322 — LOG-I - Impact Study of LOG-AFTER Software on Long-term Monitoring of Former Patients (LOG-I - LOG-Impact Study) · NA · recruiting
NCT07188311 — Pucotenlimab Combined With Lenvatinib and Chemotherapy in the Treatment of Advanced, Relapsed/Refractory Hepatoblastoma · NA · recruiting

Other Dana-Farber Cancer Institute trials

Trials by the same sponsor.

NCT07519200 — Sexual Health and Rehabilitation for Women With Metastatic Breast Cancer (SHARE-MC): An Educational Intervention · NA · not yet recruiting
NCT07499999 — Randomized Double-Blind Phase II Trial of Baby Exemestane Versus Baby Tamoxifen in Post-Menopausal Women at High Risk fo · Phase 2 · not yet recruiting
NCT05825469 — Development and Testing of Nutritional Algorithms (NACHO) · NA · not yet recruiting
NCT07516353 — my.naviGATE: A Guide to After-Treatment Effects for Adolescents and Young Adults · NA · not yet recruiting
NCT07513324 — Risk-adapted Therapy in HPV-positive Oropharyngeal Cancer Using Circulating Tumor (ct) HPV DNA Profiling (ReACT 2.0) · Phase 2 · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT04479514 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Dana-Farber Cancer Institute
Last refreshed: 1 May 2025

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04479514.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing